Cryo-Cell International (OTCMKTS:CCEL) Shares Cross Above 50-Day Moving Average of $6.03

Cryo-Cell International, Inc. (OTCMKTS:CCELGet Free Report)’s share price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $6.03 and traded as high as $6.10. Cryo-Cell International shares last traded at $5.89, with a volume of 2,900 shares changing hands.

Cryo-Cell International Price Performance

The company has a market cap of $48.83 million, a PE ratio of 21.04 and a beta of 0.33. The company has a 50-day moving average of $6.03 and a 200 day moving average of $4.94.

Cryo-Cell International (OTCMKTS:CCELGet Free Report) last released its quarterly earnings results on Friday, July 14th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.10. The company had revenue of $7.77 million during the quarter. Cryo-Cell International had a negative return on equity of 168.11% and a net margin of 7.38%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cryo-Cell International stock. Cerity Partners LLC acquired a new position in Cryo-Cell International, Inc. (OTCMKTS:CCELFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 19,563 shares of the company’s stock, valued at approximately $83,000. Cerity Partners LLC owned about 0.23% of Cryo-Cell International at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Cryo-Cell International Company Profile

(Get Free Report)

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.

Read More

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with's FREE daily email newsletter.